Simcere Pharmaceutical Group Limited (HK:2096) has released an update.
Simcere Pharmaceutical Group Limited has announced that their innovative anti-SARS-CoV-2 drug, XIANNUOXIN® (Simnotrelvir Tablets/Ritonavir Tablets), has received regular approval from China’s National Medical Products Administration to treat adults with mild to moderate COVID-19. This makes XIANNUOXIN® the first oral anti-SARS-CoV-2 medication to achieve regular approval status in China, following a technology transfer agreement for exclusive development and commercialization rights. The drug has shown to significantly reduce viral load and improve recovery times in clinical studies.
For further insights into HK:2096 stock, check out TipRanks’ Stock Analysis page.
